Netherton Syndrome Clinical Trial Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight's "Netherton Syndrome Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Netherton Syndrome pipeline landscape. It covers the Netherton Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Netherton Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Netherton Syndrome Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight [https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Netherton Syndrome Pipeline Report

* In December 2025- Sixera Pharma conducted a phase I/II trial a topical skin cream with the active substance SXR1096 will be tested in patients with Netherton syndroms, a rare inflammatory skin disease. SXR1096 is a specific and potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14 - all recognised as up-regulated and causing the disease state in Netherton syndrome patients. Patients will be treated for one month with active cream and placebo cream at different areas of the skin.
* DelveInsight's Netherton Syndrome Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Netherton Syndrome treatment.
* The leading Netherton Syndrome Companies, such as TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharma and others.
* Promising Netherton Syndrome Therapies such as QRX003, SPEVIGO (spesolimab/BI 655130), LM-030 (BPR277), DS-2325a, Pimecrolimus , and others.

Want to know which companies are leading innovation in Netherton Syndrome? Dive into the full pipeline insights @ Netherton Syndrome Clinical Trials Assessment [https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Netherton Syndrome Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Netherton Syndrome Pipeline Report also highlights the unmet needs with respect to the Netherton Syndrome.

Netherton Syndrome Overview

Netherton Syndrome is a rare, inherited genetic disorder that primarily affects the skin, hair, and immune system. It is caused by mutations in the SPINK5 gene, which leads to a deficiency of the protein LEKTI (lympho-epithelial Kazal-type-related inhibitor)-a key regulator of skin barrier function and inflammation.

Netherton Syndrome Emerging Drugs Profile

* QRX003: Quoin Pharmaceuticals

QRX003 is a topical lotion, formulated with a proprietary Invisicare Registered delivery technology, and contains a broad- spectrum serine protease inhibitor, whose mechanism of action is intended to perform the function of a specific protein, called LEKTI. The absence of LEKTI in Netherton patients leads to excessive skin shedding resulting in a highly porous and compromised skin barrier. QRX003 is designed to lead to a more normalized skin shedding process and the formation of a stronger and more effective skin barrier. When applied daily to the skin, the active ingredient in QRX003 performs the function of the missing LEKTI protein and down regulates, but does not completely stop, the activity of the Kallikreins, leading to a more normalized skin shedding process and the formation of a stronger and more effective skin barrier. The serine protease inhibitor in QRX003 also acts as a potent anti-inflammatory and antioxidant. The Invisicare Registered delivery technology offers immediate protection against TEWL and environmental agents. Uniquely this technology both moisturizes the skin while providing a protective barrier. In March 2024, Quoin Pharmaceuticals Ltd announced clearance from the U.S. Food and Drug Administration (FDA) to recruit teen subjects aged 14 years and older into its two ongoing clinical trials for QRX003, which is being developed as a potential treatment for Netherton Syndrome (NS). Both trials are being conducted under Quoin's open Investigational New Drug Application (IND) for QRX003. Currently, the drug is in Phase II/III stage of its development for the treatment of Netherton Syndrome.

* SXR-1096: Sixera Pharma

SXR1096 is a first-in-class, potent and selective small molecule inhibitor of kallikreins 5, 7 and 14 (KLK5, 7 and 14). The compound is formulated in a proprietary skin cream formulation designed for daily use in patients with rare skin conditions. Due to the inborn lack of the protease inhibitor LEKTI, KLK 5, 7 and 14 are overactive in the outermost layer of the skin in patients with Netherton syndrome. These drug targets can best be reached by applying the pharmaceutical directly on the skin. The disease is manifest from birth and can be life threatening in newborns. In July 2022, SXR-1096 received rare pediatric disease designation from US FDA for the treatment of Netherton syndrome. Currently, the drug is in Phase I/II stage of its development for the treatment of Netherton Syndrome.

If you're tracking ongoing Netherton Syndrome Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Netherton Syndrome Treatment Drugs [https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Netherton Syndrome Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Netherton Syndrome with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Netherton Syndrome Treatment.
* Netherton Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Netherton Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Netherton Syndrome market.

Netherton Syndrome Companies

TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharma and others.

Netherton Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Netherton Syndrome Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Netherton Syndrome Pipeline Report covers it all - check it out now @ Netherton Syndrome Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Netherton Syndrome Pipeline Report

* Coverage- Global
* Netherton Syndrome Companies- TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharma and others.
* Netherton Syndrome Therapies- QRX003, SPEVIGO (spesolimab/BI 655130), LM-030 (BPR277), DS-2325a, Pimecrolimus , and others.
* Netherton Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Netherton Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Netherton Syndrome Treatment landscape in this detailed analysis @ Netherton Syndrome Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Netherton Syndrome: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Netherton Syndrome - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Mid Stage Products (Phase II/III)
* QRX003: Quoin Pharmaceuticals
* Early Stage Products (Phase I/II)
* SXR-1096: Sixera Pharma
* Preclinical and Discovery Stage Products
* Inactive Products
* Netherton Syndrome Key Companies
* Netherton Syndrome Key Products
* Netherton Syndrome- Unmet Needs
* Netherton Syndrome- Market Drivers and Barriers
* Netherton Syndrome- Future Perspectives and Conclusion
* Netherton Syndrome Analyst Views
* Netherton Syndrome Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=netherton-syndrome-clinical-trial-pipeline-accelerates-as-5-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/netherton-syndrome-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.